0001209191-18-054150.txt : 20181003 0001209191-18-054150.hdr.sgml : 20181003 20181003200025 ACCESSION NUMBER: 0001209191-18-054150 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181001 FILED AS OF DATE: 20181003 DATE AS OF CHANGE: 20181003 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SLATTERY JOSEPH P CENTRAL INDEX KEY: 0001246530 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19437 FILM NUMBER: 181106687 MAIL ADDRESS: STREET 1: C/O TRANSENTERIX, INC. STREET 2: 635 DAVIS DRIVE, SUITE 300 CITY: MORRISVILLE STATE: NC ZIP: 27560 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TRANSENTERIX INC. CENTRAL INDEX KEY: 0000876378 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 112962080 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 635 DAVIS DRIVE STREET 2: SUITE 300 CITY: MORRISVILLE STATE: NC ZIP: 27560 BUSINESS PHONE: 919-765-8400 MAIL ADDRESS: STREET 1: 635 DAVIS DRIVE STREET 2: SUITE 300 CITY: MORRISVILLE STATE: NC ZIP: 27560 FORMER COMPANY: FORMER CONFORMED NAME: SafeStitch Medical, Inc. DATE OF NAME CHANGE: 20080211 FORMER COMPANY: FORMER CONFORMED NAME: CELLULAR TECHNICAL SERVICES CO INC DATE OF NAME CHANGE: 19930328 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-10-01 0 0000876378 TRANSENTERIX INC. TRXC 0001246530 SLATTERY JOSEPH P C/O TRANSENTERIX, INC. 635 DAVIS DRIVE, SUITE 300 MORRISVILLE NC 27560 0 1 0 0 EVP and CFO Common Stock 2018-10-01 4 M 0 11951 1.42 A 11951 D Common Stock 2018-10-01 4 M 0 9375 1.53 A 21326 D Common Stock 2018-10-01 4 M 0 6250 2.45 A 27576 D Common Stock 2018-10-01 4 M 0 11250 2.94 A 38826 D Common Stock 2018-10-01 4 M 0 13750 3.82 A 52576 D Common Stock 2018-10-01 4 M 0 3575 4.02 A 56151 D Common Stock 2018-10-01 4 S 0 56151 5.73 D 0 D Common Stock 2018-10-02 4 M 0 8500 1.42 A 8500 D Common Stock 2018-10-02 4 S 0 8500 5.77 D 0 D Common Stock 25000 I By IRA Stock Option 1.42 2018-10-01 4 M 0 11951 0.00 D 2027-02-02 Common Stock 11951 245334 D Stock Option 1.53 2018-10-01 4 M 0 9375 0.00 D 2026-10-25 Common Stock 9375 78125 D Stock Option 2.45 2018-10-01 4 M 0 6250 0.00 D 2025-10-28 Common Stock 6250 27084 D Stock Option 2.94 2018-10-01 4 M 0 11250 0.00 D 2025-02-04 Common Stock 11250 28126 D Stock Option 3.82 2018-10-01 4 M 0 13750 0.00 D 2026-02-12 Common Stock 13750 116875 D Stock Option 4.02 2018-10-01 4 M 0 3575 0.00 D 2024-04-21 Common Stock 3575 461426 D Stock Option 1.42 2018-10-02 4 M 0 8500 0.00 D 2027-02-02 Common Stock 8500 236834 D The transaction occurred pursuant to a written trading plan dated November 29, 2017 meeting the requirements of Rule 10b5-1(c). The sale price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.64 to $5.805 inclusive. The reporting person undertakes to provide to TransEnterix, Inc., any security holder of TransEnterix, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. The sale price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.75 to $5.78. inclusive. The reporting person undertakes to provide to TransEnterix, Inc., any security holder of TransEnterix, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Following the sales on October 1, 2018, the reporting person continues to beneficially own 25,000 shares of the company's common stock. The reporting person also holds stock options to acquire 1,749,470 shares of common stock, of which approximately 26% are vested, and restricted stock units representing an additional 595,777 shares of common stock subject to forfeiture restrictions. Vests 25% on the first anniversary of the date of grant and 1/48th of the entire award monthly on the vesting date anniversary for 36 months, subject to acceleration as set forth in the Incentive Plan and the reporting person's Employment Agreement with the Company. Fully vested. /s/ Joshua Weingard, as Attorney-in-Fact for Joseph Slattery 2018-10-03